Skip to content
SPACListing
CompletedNasdaq

Vesicor Therapeutics Holdings, Inc.BKHA

Class A BKHAUnits BKHAURights BKHARCIK 0002000775

Cash in trust

$26.0M

$25,993,300 at Aug 31, 2026

Trust per share

$12.24

Redemption value

IPO

Mar 2024

$69.0M raised

Combination deadline

Jun 22, 2025

Deadline passed

Filings on record

122

Latest Nov 20, 2026

Business combination

Target
Not disclosed in an indexed filing
Announced
Apr 29, 2025
Closed
Nov 16, 2026

Overview

Vesicor Therapeutics Holdings, Inc. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0002000775. It completed its initial public offering in Mar 2024, raising $69.0M in gross proceeds and listing on Nasdaq. Class A shares trade under the ticker BKHA, units under BKHAU, rights under BKHAR on Nasdaq. The vehicle is sponsored by Black Hawk. Business combination closed; the company trades under a new ticker.

Reading the filings

Arithmetic on what Vesicor Therapeutics Holdings, Inc. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Trust versus the $10 unit

    The trust holds $12.24 per public share, 22.4% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.

Where it is in its life

From listing to the date Vesicor Therapeutics Holdings, Inc. must close a deal, extend again, or return the trust. The marker is today.

IPO Mar 22, 2024Deadline Jun 22, 2025973 days in516 days past the deadline
How busy it has been

Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.

16802023-122026-11

122 filings in all. 16 in the last three months, against a busiest month of 16.

News on Vesicor Therapeutics Holdings, Inc.

Last 90 days

SEC filing history

Free tier: filings older than 24 hours
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0001905106-26-000192

    Nov 16, 2026

    4d ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001104659-26-125690

    Nov 12, 2026

    8d ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001628280-26-072383

    Nov 9, 2026

    10d ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001140361-26-042051

    Nov 5, 2026

    15d ago

    View on EDGAR ↗
  • 8-K

    Other events

    Item 8.01 · Accession 0001829126-26-011490

    Oct 23, 2026

    28d ago

    View on EDGAR ↗
  • 8-K

    Submission of matters to a vote of security holders

    Item 5.07 · Accession 0001829126-26-011077

    Oct 13, 2026

    1mo ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001140361-26-038899

    Oct 7, 2026

    1mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001829126-26-010813

    Oct 6, 2026

    1mo ago

    View on EDGAR ↗
  • 425

    Business-combination communication

    Accession 0001829126-26-010391

    Sep 24, 2026

    1mo ago

    View on EDGAR ↗
  • 8-K

    Entry into a material definitive agreement

    Items 1.01, 3.02, 9.01 · Accession 0001829126-26-010385

    Sep 24, 2026

    1mo ago

    View on EDGAR ↗
  • 8-K

    Other events

    Item 8.01 · Accession 0001829126-26-010313

    Sep 22, 2026

    1mo ago

    View on EDGAR ↗
  • 424B4

    Final IPO prospectus

    Accession 0001829126-26-010292

    Sep 22, 2026

    1mo ago

    View on EDGAR ↗
  • EFFECT

    Notice of effectiveness

    Accession 9999999995-26-002988

    Sep 18, 2026

    2mo ago

    View on EDGAR ↗
  • S-4/A

    S-4/A

    Accession 0001829126-26-009732

    Sep 4, 2026

    2mo ago

    View on EDGAR ↗
  • 8-K

    Entry into a material definitive agreement

    Items 1.01, 2.03, 3.02, 9.01 · Accession 0001829126-26-009347

    Aug 26, 2026

    2mo ago

    View on EDGAR ↗
  • 8-K

    Other events

    Item 8.01 · Accession 0001829126-26-009270

    Aug 24, 2026

    2mo ago

    View on EDGAR ↗
  • S-4/A

    S-4/A

    Accession 0001829126-26-008251

    Aug 1, 2026

    3mo ago

    View on EDGAR ↗
  • 8-K

    Other events

    Item 8.01 · Accession 0001829126-26-007744

    Jul 22, 2026

    4mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001829126-26-007603

    Jul 15, 2026

    4mo ago

    View on EDGAR ↗
  • S-4/A

    S-4/A

    Accession 0001829126-26-007231

    Jul 3, 2026

    4mo ago

    View on EDGAR ↗
  • S-4/A

    S-4/A

    Accession 0001829126-26-006338

    Jun 11, 2026

    5mo ago

    View on EDGAR ↗
  • 8-K

    Entry into a material definitive agreement

    Items 1.01, 2.03, 3.02, 9.01 · Accession 0001829126-26-004870

    May 8, 2026

    6mo ago

    View on EDGAR ↗
  • S-4/A

    S-4/A

    Accession 0001829126-26-004346

    May 1, 2026

    6mo ago

    View on EDGAR ↗
  • 10-K/A

    10-K/A

    Accession 0001829126-26-004046

    Apr 28, 2026

    6mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001829126-26-003670

    Apr 20, 2026

    7mo ago

    View on EDGAR ↗
  • NT 10-Q

    Late quarterly report notification

    Accession 0001829126-26-003495

    Apr 14, 2026

    7mo ago

    View on EDGAR ↗
  • 8-K

    Notice of delisting or failure to satisfy a listing rule

    Item 3.01 · Accession 0001829126-26-003042

    Apr 1, 2026

    7mo ago

    View on EDGAR ↗
  • 8-K

    Regulation FD disclosure

    Items 5.02, 7.01, 9.01 · Accession 0001829126-26-002413

    Mar 17, 2026

    8mo ago

    View on EDGAR ↗
  • 10-K

    Annual report

    Accession 0001829126-26-002021

    Mar 6, 2026

    8mo ago

    View on EDGAR ↗
  • S-4/A

    S-4/A

    Accession 0001829126-26-001934

    Mar 5, 2026

    8mo ago

    View on EDGAR ↗

Pro

2 filings from the last 24 hours are hidden

Pro accounts see every filing minutes after EDGAR publishes it, instead of a day later.

Cancel any time. Billed monthly in USD.

Vesicor Therapeutics Holdings, Inc.: questions answered

What is Vesicor Therapeutics Holdings, Inc. (BKHA)?

Vesicor Therapeutics Holdings, Inc. is a special purpose acquisition company incorporated and registered with the SEC under CIK 0002000775. It completed its initial public offering in Mar 2024, raising $69.0M in gross proceeds and listing on Nasdaq. Class A shares trade under the ticker BKHA, units under BKHAU, rights under BKHAR on Nasdaq. The vehicle is sponsored by Black Hawk. Business combination closed; the company trades under a new ticker.

How much does Vesicor Therapeutics Holdings, Inc. hold in trust?

Approximately $25,993,300, or about $12.24 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must Vesicor Therapeutics Holdings, Inc. complete a merger?

By Jun 22, 2025. If no combination closes by then the sponsor must seek a further extension or wind the vehicle up and return the trust.

What happens if Vesicor Therapeutics Holdings, Inc. does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in Vesicor Therapeutics Holdings, Inc., and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $12.24 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

What tickers does Vesicor Therapeutics Holdings, Inc. trade under?

Class A shares trade as BKHA on Nasdaq, the units as BKHAU, with rights as BKHAR. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.

Is the trust value the same as the share price for Vesicor Therapeutics Holdings, Inc.?

No, and the gap between them is the whole trade. Trust per share is a disclosed, contractual figure of $12.24, being what a redeeming holder receives. The market price is whatever the shares change hands at: most recently $1.85, a spread to the redemption value. Quotes on this site are delayed and indicative; confirm on your own venue before trading.

Who sponsors Vesicor Therapeutics Holdings, Inc., and what is their track record?

Black Hawk is the sponsor entity, part of the Black Hawk franchise. This is the only vehicle we have attributed to that sponsor.

Is Vesicor Therapeutics Holdings, Inc. tradeable, and where?

Yes. BKHA returned a live quote of $1.85 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.

Is Vesicor Therapeutics Holdings, Inc. a good investment?

That is not a question this site answers. Vesicor Therapeutics Holdings, Inc. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this Vesicor Therapeutics Holdings, Inc. data come from?

Filings Vesicor Therapeutics Holdings, Inc. submitted to the SEC under CIK 0002000775: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Nov 20, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.